IGFBPI Protéine

N° du produit ABIN7849663

Cette protéine Recombinant IGFBPI est produite dans Escherichia coli (E. coli).

Aperçu rapide pour IGFBPI Protéine (ABIN7849663)

Antigène: IGFBPI (Insulin-Like Growth Factor Binding Protein 1 (IGFBPI))

Type de proteíne: Recombinant

Origine: Humain

Source: Escherichia coli (E. coli)

Application: SDS-PAGE (SDS), ELISA

Pureté: >90 % by SDS-PAGE

Détail du produit

Fonction: Recombinant Human IGFBP1Protein

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: 10 mM Tris-HCl pH 9.0.

Stock: 4 °C,-20 °C

Stockage commentaire: Ship at 4°C. Upon receipt, aliquot and store at -20°C for long term. Avoid repeated freeze and thaw cycles.

Détail du antigène

Antigène: IGFBPI (Insulin-Like Growth Factor Binding Protein 1 (IGFBPI))

Autre désignation: IGFBP1

Sujet:

Synonyms: Insulin-like Growth Factor Binding Protein 1, IGFBP-1, AFBP, Alpha pregnancy associated endometrial globulin, Amniotic fluid binding protein, Binding protein 25, Binding protein 26, Binding protein 28, Growth hormone independent binding protein, hIGFBP 1, hIGFBP1, IBP 1, IBP1, IGF binding protein 1, IGF BP25, IGFBP 1, Placental protein 12, PP12

Description: Recombinant human Insulin Like Growth Factor Binding 1 protein with molecular weight of 31 kDa.

Background: Insulin-like growth factor-binding protein 1 (IBP-1) also known as placental protein 12 (PP12) is a protein that in humans is encoded by the IGFBP1 gene. IGFBP1 expression after treatment of E2 was examined in a HepG2 hepatoma cell line. Meanwhile, both mRNA and protein expressions of IGFBP1 were elevated in placenta and liver tissues. Furthermore, the level of IGFBP1 in the HepG2 cell line was elevated by the treatment of E2, whereas this effect was blocked by estrogen receptor antagonist ICI 182780. Among clinical variables, the IGFBP1 level was correlated with HDL-C. IGFBP1 alone (cutoff 20.86 ng/mL) demonstrated a sensitivity of 0.448 and specificity of 0.933 in predicting CAD. Combination of IGFBP1 and HDL-C had a sensitivity of 0.821 and specificity of 0.800 in predicting CAD. Conclusions. Circulating IGFBP1 level positively correlated with the severity of CAD. IGFBP1, when combined with HDL-C, might be useful in screening for high risk CAD patients.

Pathways: Myometrial Relaxation and Contraction, ER-Nucleus Signaling, Growth Factor Binding